Investment Thesis
Enovis is unprofitable with deteriorating earnings (-39% EPS decline YoY) despite 6.7% revenue growth, indicating poor expense control and low-quality growth. Critical debt servicing risk emerges from an interest coverage ratio of 0.7x combined with negative free cash flow of -28.9M, while minimal cash of 33.1M relative to 1.3B long-term debt creates significant refinancing vulnerability.
Strengths
- Revenue growing 6.7% year-over-year in orthopedic appliances sector
- Strong gross margin of 62% demonstrates pricing power and manufacturing efficiency
- Current ratio of 2.04x indicates adequate short-term liquidity coverage
Risks
- Operating margin of 1.1% is dangerously thin; company is unprofitable with -1.5% net margin
- Interest coverage ratio of 0.7x means operating income cannot service debt obligations
- Negative free cash flow of -28.9M is unsustainable; company is burning cash despite positive operations
- Only 33.1M cash against 1.3B long-term debt creates acute refinancing and covenant default risk
- EPS declining 39% year-over-year signals deteriorating profitability and shareholder value destruction
Key Metrics to Watch
- Quarterly free cash flow trend and cash balance depletion rate
- Operating margin expansion and ability to reach breakeven profitability
- Debt covenant compliance and refinancing obligations in next 12-24 months
- Operating expense ratio reduction initiatives and restructuring progress
Financial Metrics
Revenue
589.2M
Net Income
-8.8M
EPS (Diluted)
$-0.15
Free Cash Flow
-28.9M
Total Assets
3.8B
Cash
33.1M
Profitability Ratios
Gross Margin
62.0%
Operating Margin
1.1%
Net Margin
-1.5%
ROE
-0.6%
ROA
-0.2%
FCF Margin
-4.9%
Balance Sheet & Liquidity
Current Ratio
2.04x
Quick Ratio
1.05x
Debt/Equity
0.90x
Debt/Assets
61.4%
Interest Coverage
0.71x
Long-term Debt
1.3B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T10:28:24.967325 |
Data as of: 2026-04-03 |
Powered by Claude AI